DeDora Capital Inc. Buys 959 Shares of Amgen Inc. (NASDAQ:AMGN)

DeDora Capital Inc. boosted its stake in Amgen Inc. (NASDAQ:AMGNFree Report) by 22.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,308 shares of the medical research company’s stock after purchasing an additional 959 shares during the period. DeDora Capital Inc.’s holdings in Amgen were worth $1,509,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in shares of Amgen during the 3rd quarter worth $26,000. Briaud Financial Planning Inc purchased a new position in shares of Amgen during the 3rd quarter worth $26,000. BOK Financial Private Wealth Inc. purchased a new position in shares of Amgen during the 4th quarter worth $29,000. United Community Bank purchased a new position in shares of Amgen during the 4th quarter worth $29,000. Finally, Providence Capital Advisors LLC purchased a new position in shares of Amgen during the 3rd quarter worth $30,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of analyst reports. UBS Group lifted their target price on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday. Oppenheimer restated an “outperform” rating and set a $350.00 target price on shares of Amgen in a research note on Thursday, February 1st. Morgan Stanley lifted their target price on shares of Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday. TD Cowen lowered their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group lifted their target price on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $305.05.

Read Our Latest Analysis on AMGN

Amgen Price Performance

Shares of Amgen stock traded up $32.90 during trading hours on Friday, reaching $311.29. The company’s stock had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The firm has a 50 day moving average price of $274.95 and a 200-day moving average price of $281.50. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The stock has a market cap of $166.97 billion, a P/E ratio of 44.47, a P/E/G ratio of 2.69 and a beta of 0.60.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 145.62%. The firm’s revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.98 EPS. On average, analysts predict that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 2.89%. Amgen’s payout ratio is 128.57%.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.46% of the stock is currently owned by insiders.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Read More

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.